FDA Grants Fast Track Status to Aegle Therapeutics’ AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa

Oct 01, 2020

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102™ for the treatment of patients with DEB. Evangelos Badiavas, MD, PhD, Chief Scientific Officer at Aegle Therapeutics said, “This designation will expedite the development and regulatory review of AGLE-102 and highlights the importance…

Read more >